ArticleJournal of evaluation in clinical practice2026
Long-Term Adherence and Drug Utilisation Patterns Among New Users of Anti-Hyperlipidemic Monotherapy: Development of a Risk Prediction Model.
Article in Journal of evaluation in clinical practice, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
rationaleReal-world long-term adherence and drug patterns are essential in hyperlipidemia management. However, the evidence was unclear. AIMS AND
objectivesThis study aimed to assess long-term adherence, drug usage patterns of anti-hyperlipidemic monotherapy, associated risk factors, and develop risk prediction models.
methodsWe performed a retrospective inception cohort study utilising data from the University of Groningen's IADB.nl dispensing database. The study included new users of anti-hyperlipidemic monotherapies-simvastatin, pravastatin, fluvastatin, atorvastatin, rosuvastatin, and fibrates, with approximately a follow-up to 10 years. Using logistic regression, we developed risk prediction models for adherence and drug utilisation patterns, including discontinuation, continuation, switching, and add-on therapies.
resultsSimvastatin users demonstrated high prevalence of high adherence throughout the study (83.6%-90.2%) and had the highest continuation rate (39.2%) with minimal switching or add-on therapy use. Individuals aged 40 and older exhibited better adherence and higher continuation rates. Male patients had lower adherence but higher continuation rates. High adherence was associated with both high continuation and increased switching or add-on therapy use. Patients using diabetes medications had better adherence, higher continuation, and lower switching and add-on rates, whereas those on antiparkinson drugs had lower continuation rates. Recent initiators showed better continuation and lower switching or add-on rates.
conclusionsSimvastatin users demonstrated higher adherence and continuation rates compared to other anti-hyperlipidemic monotherapy users. Factors including older age, female sex, and diabetes medications use were associated with improved adherence. Sensitivity analyses using equivalent dosing regimens yielded consistent findings. These insights into adherence and drug patterns are critical for informing personalised strategies to optimise cardiovascular disease prevention.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.